Overview

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

Status:
Active, not recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ivonne Schulman
Joshua M Hare

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)